- Home
- NSTS vs RLYB Comparison
NSTS vs RLYB Comparison
Compare NSTS & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSTS | RLYB |
|---|---|---|
| Founded | 1921 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.2M | 28.7M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NSTS | RLYB |
|---|---|---|
| Price | $11.60 | $8.22 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.8K | ★ 250.4K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $256,000.00 | ★ $858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 43.00 |
| 52 Week Low | $10.73 | $0.22 |
| 52 Week High | $13.06 | $11.49 |
Technical Indicators
Market Signals| Indicator | NSTS | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 32.84 | 50.51 |
| Support Level | $11.43 | $0.48 |
| Resistance Level | $12.30 | $11.49 |
| Average True Range (ATR) | 0.14 | 0.68 |
| MACD | -0.05 | -0.45 |
| Stochastic Oscillator | 0.02 | 2.97 |
Price Performance
Historical ComparisonAbout NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.